MYELOPROLIFERATIVE DISORDERS

This early-phase study tests an experimental drug, JNJ-88549968, designed to help the immune system attack cancer cells with a specific genetic change (CALR mutation). About 220 adults with essential thrombocythemia or myelofibrosis will receive the drug to find a safe dose and c…

This early-phase study tests whether specially trained immune cells (CIML NK cells) given after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back. About 15 adults with high-risk acute myeloid leukemia, myelodysplastic syndrome, or relate…

This study tests whether a new way of giving three drugs (ATG, tacrolimus, and methotrexate) can prevent a serious side effect called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial will enroll 29 adults aged 18-60 who have a matched don…

This study tests a two-step method of giving an anti-rejection drug (ATG) along with standard medications to prevent severe graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 56 adults aged 18-75 will participate. The goal is to …

This study is testing a new platform that uses advanced genetic and functional tests to better understand tumors from 300 people with various high-risk cancers, including leukemia, myeloma, and pancreatic cancer. The goal is to see if this detailed analysis can change the recomme…

This study tests whether people with myeloproliferative neoplasms (a type of blood disorder) can stick with a 12-week program that teaches healthier eating and more physical activity. About 30 adults will take part. The main goal is to see if at least 70% of participants can comp…

This study is for people with myeloproliferative neoplasms (MPNs), a group of blood cancers that raise the risk of dangerous blood clots. Researchers want to see if a marker called calprotectin in the blood can help predict who will get a clot. 300 participants will be followed o…

This study is a long-term registry for people with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, surveys, and insurance data from 5,000 participants over at least five years to understand how the disease progresses an…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study is collecting blood, bone marrow, and tissue samples from over 1,000 people with blood cancers like leukemia and myeloma. Researchers will use advanced lab techniques to find unique markers (biomarkers) in each person's cancer. The goal is to better understand these di…

This study looks at blood cancer cells from 250 patients to understand which drugs might work best. Researchers will test many approved and experimental drugs on these cells in the lab. The goal is to find new treatment targets and match them to each patient's cancer type. This i…